NCT Number: NCT05053152
Phase: Phase 2
Trial Summary: This phase II trial tests whether relugolix and radiation therapy works to shrink tumors in patients with prostate cancer that has spread in a limited way to 1 to 5 other parts of – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): NRG Oncology|National Cancer Institute (NCI)
Acronym: NRG PROMETHEAN
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives